Tg Therapeutics (TGTX) traded up 1.9 % during a 24 hours period ending at 06:57 PM Central Europe on Monday 26th. One Tg Therapeutics stock can currently be bought for about USD 53.92 on popular exchanges. Current supply of Tg Therapeutics stocks is 153.1 mn. Tg Therapeutics has a current market capitalization of USD 8.3 bn and approximately USD 107.2 mn worth of Tg Therapeutics was traded on exchanges in the last 24 hours. Since last month end, Tg Therapeutics has traded -5.82 % down. Simple moving average of last 200 days is at USD 43.09. The highest price of past 52 weeks was recorded at USD 59.3 on 07/09/2026. 52 weeks low was at USD 26.76 on 03/12/2026.

Here is how related stocks have performed in the past 24 hours:

  • Regal Rexnord (RRX) traded down -0.53 % and now trades at USD 151.56. Regal Rexnord has a market capitalisation of USD 9.9 bn. Regal Rexnord has a current price to earnings ratio of 30.68.

  • Donaldson (DCI) traded down -1.54 % and now trades at USD 86.29. Donaldson has a market capitalisation of USD 9.8 bn. Donaldson has a current price to earnings ratio of 22.06.

  • Cullen/frost Bankers (CFR) traded down -0.4 % and now trades at USD 159.18. Cullen/frost Bankers has a market capitalisation of USD 9.8 bn. Current price/earnings ratio for Cullen/frost Bankers is 14.87.

  • Affiliated Managers (AMG) traded down -3.06 % and now trades at USD 383.42. Affiliated Managers has a market capitalisation of USD 9.9 bn. Current price/earnings ratio for Affiliated Managers is 13.38.

  • Advanced Drainage (WMS) traded down -0.4 % and now trades at USD 131.17. Advanced Drainage has a market capitalisation of USD 9.8 bn. Advanced Drainage has a current price to earnings ratio of 22.32.

About Tg Therapeutics

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New York, United States, specializing in the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other therapeutic needs. The company is actively pursuing two therapies targeted towards hematological malignancies, specifically relapsed and refractory non-Hodgkins lymphoma. You can find more information about their activities and offerings on their official website, www.tgtherapeutics.com , or through trading on the Nasdaq stock exchange.